Actionable news
0
All posts from Actionable news
Actionable news in MRK: MERCK & CO. Inc,

Bristol-Myers shares slump after failed AstraZeneca drug trial

July 27 (Reuters) - Bristol-Myers Squibb Co shares fell 5 percent on Thursday as investors bet that a failed cancer-drug trial at AstraZeneca would have negative implications for Bristol-Myers' similar immunotherapy treatment regimen.

AstraZeneca's Mystic study, released early on Thursday, looked at a combination of cancer drugs in treatment of non-small cell lung cancer and found it was no more effective than chemotherapy in improving progression-free survival.

Bristol-Myers is studying the combination of two of its top drugs, Opdivo and Yervoy. The company's shares tumbled 5 percent in premarket trading to $53.26.

Bristol-Myers said the Mystic trials and its own CheckMate-227 trials had different designs, drugs, dosing and scheduling.

"It’s difficult to make direct comparisons or draw conclusions from one...


More